Publication of insider information pursuant to Art. 17 MAR

Jena, Germany | January 22, 2026 | Carl Zeiss Meditec AG

In the first 3 months of fiscal year (FY) 2025/26 ending December 31, 2025, Carl Zeiss Meditec AG (ISIN: DE0005313704) recorded preliminary revenue of € 467 million (prior year: € 490 million). The revenue decline was mainly caused by negative currency effects. Preliminary operating profit (Earnings before interest, taxes and amortization of intangible assets from purchase price allocations = EBITA) amounted to € 8 million (prior year: € 35 million).

Several reasons for softer business performance in the first 3 months can be identified: the exceptionally strong equipment deliveries in the last month of FY 2024/25, which resulted in a softer start to the new FY; significant currency headwinds; the revenue loss from a bifocal intraocular (IOL) in China following its withdrawal from the volume-based-procurement tender, as previously disclosed in the FY 2024/25 earnings call on December 11, 2025; an increasingly weak investment environment in the Americas region amid heightened geopolitical volatility; and a later start to the seasonal peak for refractive treatment packs by hospitals in China due to the late timing of the Chinese New Year holidays. In addition, the upcoming new nation-wide volume-based procurement tender for the IOL business in China is expected to cause significant price erosion due to an increased level of Chinese local competition.

Given the current high level of uncertainties surrounding geopolitical developments, trade barriers and regulatory changes, previous FY 2025/26 guidance will likely not be achieved and is currently under review, while among other factors the outcomes of the IOL re-registration process and new nation-wide volume-based-procurement tender in China as well as the winter seasonal peak for refractive treatment packs are pending (previous guidance: around € 2.3 billion in revenue and an EBITA margin (EBITA/Revenue) of 12.5%). Management will present an update on further re-organization and expense measures together with refined FY 2025/26 guidance as soon as possible and no later than the 6-month earnings call on May 12, 2026.

The quarterly statement for 3M 2025/26 will be published on February 12, 2026.